Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Saved in:
Bibliographic Details
Title: Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.
Authors: Arikci D; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Borgulya J; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Straumann I; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Vizeli P; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Luethi D; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Thomann J; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Rudin D; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Vukalovic I; Psychiatric University Hospital, University of Basel, Basel, Switzerland.; Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland., Eckert A; Psychiatric University Hospital, University of Basel, Basel, Switzerland.; Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland., Liechti ME; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland. matthias.liechti@usb.ch.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. matthias.liechti@usb.ch., Holze F; Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland. friederike.holze@usb.ch.; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. friederike.holze@usb.ch.
Source: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2026 Jul; Vol. 51 (8), pp. 1511-1518. Date of Electronic Publication: 2026 Apr 28.
Publication Type: Journal Article; Randomized Controlled Trial; Comparative Study
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-634X (Electronic) Linking ISSN: 0893133X NLM ISO Abbreviation: Neuropsychopharmacology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1740-634X
DOI:10.1038/s41386-026-02428-9